Does tadalafil affect blood pressure? This is an important question for men considering this medication for erectile dysfunction or benign prostatic hyperplasia. Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, does cause mild vasodilation—widening of blood vessels—which typically results in a small reduction in blood pressure. For most healthy individuals, this effect is modest and well tolerated. However, the blood pressure-lowering properties become clinically significant when tadalafil is combined with certain medications, particularly nitrates, or in patients with pre-existing cardiovascular conditions. Understanding these effects is essential for safe use.

Does Tadalafil Affect Blood Pressure?

Tadalafil can affect blood pressure, though the effect is generally modest in most individuals. As a phosphodiesterase type 5 (PDE5) inhibitor, tadalafil causes vasodilation—the widening of blood vessels—which can lead to a small reduction in blood pressure. At licensed doses, these changes are usually not clinically significant for most people.

For most healthy individuals, this mild hypotensive effect is well tolerated and does not cause significant clinical problems. However, the blood pressure-lowering properties become clinically relevant in certain situations, particularly when tadalafil is combined with other medications that affect blood pressure or in patients with pre-existing cardiovascular conditions.

The timing and dose of tadalafil influence its cardiovascular effects. The medication is available in different strengths: on-demand tablets (typically 10 mg or 20 mg for erectile dysfunction) and daily low-dose tablets (2.5 mg or 5 mg). The blood pressure effects are dose-dependent, with higher doses potentially producing more pronounced reductions. The maximum blood pressure-lowering effect typically occurs approximately 1–2 hours after taking the medication.

It is important to note that whilst tadalafil does lower blood pressure, this is not its primary therapeutic purpose. The medication is licensed in the UK for treating erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia. In patients already taking antihypertensive medications, the additional blood pressure lowering effect is generally small. Patients concerned about blood pressure effects should discuss their individual risk factors with their GP or prescribing clinician, who can assess whether tadalafil is appropriate for their specific circumstances.

How Tadalafil Works in the Body

Tadalafil exerts its therapeutic effects through selective inhibition of phosphodiesterase type 5 (PDE5), an enzyme found predominantly in the smooth muscle of the corpus cavernosum of the penis, but also present in vascular smooth muscle throughout the body, including blood vessels in the lungs and systemic circulation. When sexual stimulation occurs, nitric oxide is released in the erectile tissue, which activates the enzyme guanylate cyclase. This leads to increased levels of cyclic guanosine monophosphate (cGMP), a chemical messenger that causes smooth muscle relaxation and increased blood flow to the penis, facilitating an erection.

PDE5 normally breaks down cGMP, thereby limiting the duration and magnitude of the erectile response. By inhibiting PDE5, tadalafil prevents the breakdown of cGMP, allowing it to accumulate and prolonging smooth muscle relaxation. This mechanism enhances erectile function in men with erectile dysfunction. Importantly, tadalafil requires sexual stimulation to be effective—it does not cause spontaneous erections, as the initial nitric oxide release is still necessary to trigger the cascade.

The same mechanism explains tadalafil's effects on blood pressure. Because PDE5 is also present in vascular smooth muscle throughout the body, inhibiting this enzyme causes mild systemic vasodilation. Blood vessels relax and widen, which reduces peripheral vascular resistance and consequently lowers blood pressure. This effect is generally modest but becomes clinically significant when combined with other vasodilating medications, particularly nitrates.

Tadalafil has a relatively long half-life of approximately 17.5 hours, which distinguishes it from other PDE5 inhibitors. This extended duration of action means the pharmacodynamic effects may persist for up to 36 hours. The prolonged presence in the circulation also means that cardiovascular effects, including blood pressure changes, may continue throughout this period. The medication is metabolised primarily by the liver through the cytochrome P450 3A4 enzyme system and excreted mainly in faeces.

Who Should Avoid Tadalafil Due to Blood Pressure Concerns

Certain patient groups should avoid tadalafil entirely due to significant blood pressure-related risks. The most critical contraindications are:

• Concurrent use of nitrate medications (such as glyceryl trinitrate, isosorbide mononitrate, or isosorbide dinitrate) or nitric oxide donors. The combination can cause severe, potentially life-threatening hypotension. This contraindication is absolute and applies to all forms of nitrates, including sublingual, oral, transdermal, and recreational forms (such as amyl nitrite "poppers").

• Concurrent use of riociguat (a soluble guanylate cyclase stimulator used for pulmonary hypertension), which can also cause severe hypotension when combined with tadalafil.

Patients with severe cardiovascular disease require careful assessment before tadalafil can be considered. Those who should generally avoid the medication include individuals with:

• Recent myocardial infarction (within 90 days)

• Unstable angina

• Angina occurring during sexual intercourse

• New York Heart Association Class 2 or greater heart failure within the past six months

• Stroke within the last 6 months

• Uncontrolled arrhythmias

• Hypotension (blood pressure below 90/50 mmHg)

• Uncontrolled hypertension

Sexual activity itself carries cardiovascular demands, and the addition of tadalafil may pose unacceptable risks in these populations.

Caution is warranted for patients taking alpha-blockers (such as doxazosin, tamsulosin, or alfuzosin) for benign prostatic hyperplasia or hypertension. The combination can cause symptomatic postural hypotension. Alpha-blocker therapy should be stable before starting tadalafil, which should be initiated at the lowest dose. For benign prostatic hyperplasia, combination with alpha-blockers is not recommended. Patients taking multiple antihypertensive medications should also be monitored closely.

Tadalafil is not recommended for patients with hereditary degenerative retinal disorders (such as retinitis pigmentosa). Patients with anatomical deformation of the penis or conditions predisposing to priapism should use with caution. Those with bleeding disorders or active peptic ulceration should also exercise caution and discuss risks with their clinician.

Safe Use of Tadalafil: Monitoring and Precautions

Before starting tadalafil, a comprehensive cardiovascular assessment is essential. Your GP or prescribing clinician should take a detailed medical history, including current medications, cardiovascular risk factors, and any history of heart disease or stroke. Blood pressure should be measured, and in some cases, additional investigations such as an electrocardiogram (ECG) may be appropriate based on cardiovascular risk and clinical judgement. NICE guidance emphasises that erectile dysfunction can be an early marker of cardiovascular disease, so its presence warrants broader cardiovascular risk assessment.

Patients should be counselled on recognising symptoms of hypotension, which may include dizziness, light-headedness (particularly when standing), fainting, blurred vision, fatigue, or nausea. These symptoms are most likely to occur within the first few hours after taking tadalafil, especially with higher doses or when combined with alcohol. If significant hypotensive symptoms occur, patients should sit or lie down immediately and seek medical attention if symptoms persist or are severe.

Important safety precautions include:

• Do not take nitrates within at least 48 hours of using tadalafil. If chest pain occurs after taking tadalafil, seek urgent medical attention and inform healthcare providers about tadalafil use before any nitrate treatment.

• Seek immediate medical attention if you experience sudden vision or hearing loss, chest pain during or after sexual activity, severe dizziness or fainting, or an erection lasting more than four hours (priapism).

• Do not combine tadalafil with other PDE5 inhibitors or erectile dysfunction treatments.

Medication interactions require careful management. Patients must inform their healthcare provider of all medications they are taking, including over-the-counter products and herbal supplements. Alpha-blockers should be stable before introducing tadalafil, and the lowest dose of tadalafil should be used initially. Potent CYP3A4 inhibitors (such as ketoconazole, ritonavir, or erythromycin) can significantly increase tadalafil levels; once-daily use is often not recommended with these medications, or dose adjustments may be required. Use caution with grapefruit juice and avoid large quantities, as it may increase tadalafil levels.

Dose adjustments may be needed for patients with kidney or liver impairment. For severe renal impairment, tadalafil once-daily is not recommended, and maximum dose restrictions apply for on-demand use. In hepatic impairment, caution is advised and dose adjustments may be necessary.

Regular monitoring is advisable for patients with borderline blood pressure or multiple cardiovascular risk factors. Home blood pressure monitoring can be useful to detect any consistent changes after starting tadalafil. Patients should be advised to moderate alcohol consumption when taking tadalafil, as alcohol itself lowers blood pressure and can compound hypotensive effects.

Patients should report any suspected side effects to their healthcare provider or through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Frequently Asked Questions